C228T mutation was found in five (27.8%) patients, and C250T mutation was found in one (5.5%) patient. TERT promoter mutations were significantly associated with the presence of two or more tumors (P=0.033) and with an European Organisation for Research and Treatment of Cancer (EORTC) risk score of 5 or higher (P=0.010) in PDD false-positive cases. Here, TERT is linked to cancer.